FBRX - Company ID 0001419041
The table below shows Forte Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Forte Biosciences, Inc. reported annual revenue of $36.00K for fiscal year 2019. That is down 99.8% from $18.04M in fiscal 2018. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.97M |
| $3.18M |
| $2.96M |
| $3.43M |
| $2.76M |
| $7.08M |
| Operating income | -$22.44M | -$18.38M | -$11.58M | -$16.12M | -$8.63M | -$12.82M |
| Income tax | $373.00K | - | - | $0.00 | - | - |
| Net income | -$22.14M | -$17.68M | -$11.25M | -$15.66M | -$8.39M | -$12.51M |
| EPS (diluted) | -$1.24 | -$0.99 | -$0.96 | -$1.37 | -$4.54 | -$6.78 |